Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)

REFERENCES

• Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, Jaffe ES, Biggar RJ. Spectrum of AIDS-associated malignant disorders [see comments]. Lancet 1998;351: 1833 — 1839.
   Google Scholar
• Tirelli U, Spina M, Gaidano G, Vaccer E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. Aids 2000;14:1675–1688.
   Google Scholar
• Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999;21(Suppl 1):527–530.
   Google Scholar
• Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, Melnick S, Munoz A. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Synch 1999;21(Suppl 1):534–541.
   Google Scholar
• Rabkin CS. Epidemiology of B-cell lymphomas. Curr Top Microbiol Immunol 1999;246:235-239, discussion 240.
   Google Scholar
• Buchbinder SP, Holmberg SD, Scheer S, Colfax G, Om P, Vittinghoff E. Combination antiretroviral therapy and in-cidence of AIDS-related malignancies. J Acquir Immune Defic Synth 1999;21(Suppl 1):523–526.
   Google Scholar
• Gerard L, Galicier L, Maillard A, Boulanger E, Quint L, Matheron S, Cardon B, Meignin V, Oksenhendler E. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Synch 2002;30:478–484.
   Google Scholar
• Carrieri MP, Pradier C, Piselli P, Piche M, Rosenthal E, Heudier P, Durant J, Serraino D. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lym-phoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003;103:142 — 144.
   Google Scholar
• Kirk 0, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhoj P, Barton SE. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406 — 3412.
   Google Scholar
• International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823— 1830.
   Google Scholar
• Klencke B, Kaplan L. Advances and future challenges in non-Hodgkin's lymphoma. Curr Opin Oncol 1998;10:422–427.
   Google Scholar
• Straus DJ. HIV-associated lymphomas. Curr Opin Oncol 1997;9:450–454.
   Google Scholar
• Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41(1-2):106–116.
   Google Scholar
• Gerard L, Galicier L, Boulanger E, Quint L, Lebrette MG, Mortier E, Meignin V, Oksenhendler E. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. Aids 2003;17:81 — 87.
   Google Scholar
• Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, Stellbrink HJ, Jaeger H, Siebert U, Horst HA. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. Aids 2003;17:1521 — 1529.
   Google Scholar
• Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma asso-ciated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group [see comments]. N Engl J Med 1997; 336:1641 — 1648.
   Google Scholar
• Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. Aids 2002;16: 531–536.
   Google Scholar
• Kaplan LD, Lee J, Scadden DT. No benefit from rituximab in a randomized phase iii trial of chop with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: updated data from aids malignancies consortium study 010. Blood 2003;102:409a.
   Google Scholar
• Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy [see comments]. Aids 1997;11:1731 — 1738.
   Google Scholar
• Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998:the Frankfurt HIV-cohort study. Eur J Med Res 2000;5:329 — 333.
   Google Scholar
• Vaccher E, Spina M, Talamini R, Zanetti M, di Gennaro G, Nasti G, Tavio M, Bernardi D, Simonelli C, Tirelli U, et al. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Chin Infect Dis 2003;37: 1556— 1564.
   Google Scholar